W STRATEGIES, LLC for ABBVIE INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars. H.R. 6: 21st Century Cures Act. H.R. 6174: Closing Loopholes for Orphan Drugs Act. Education about the value of innovative new medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program. 2016 CMS proposed rule implementing a new Part B drug payment model. H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.